You are leaving Lundbeck.com/US
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.
At a glance
Lundbeck in brief
Lundbeck is a global pharmaceutical company specialized in developing innovative treatments for brain diseases. For more than 70 years, millions of people have been treated with our products and our development and distribution of pioneering therapies continues to make a difference to people worldwide.
Lundbeck in numbers
1915
Lundbeck was founded by Hans Lundbeck in Copenhagen more than 100 years ago.
5,000+
We are more than 5,000+ employees worldwide.
70%
Our largest shareholder is the Lundbeck Foundation owning approximately 70%.
+80
Our products are registered in more than 80 countries globally.
+70
Number of years that we have been building our neuroscience expertise.
27.8 m.
Our portfolio of products reaches 27.8 million people. Estimate based on 2025 sales data for products.
+30
Number of treatments launched by Lundbeck over the years.
Global presence
We are headquartered in Denmark and located in more than 20 countries. Our products are present through partnerships in more than 80 countries around the world.
Global R&D and production
We have production facilities in Denmark, France, and Italy, as well as research and development centers in Denmark, Asia, and the United States. Our headquarters are located in Valby, Copenhagen, housing a full-value-chain R&D center and production facilities.
Total number of employees 2025
We have employees in more than 20 countries, and employ approximately 5,300 people across the value chain.
Ownership
In 1999, Lundbeck’s shares were listed on Nasdaq Copenhagen. Our largest shareholder is the Lundbeck Foundation, which holds approximately 70% of the shares. The Foundation annually grants about DKK 500 million to support medical research and educational and communication activities.
Key financial figures
Our 2025 revenue reached a total of more than DKK 24.6 billion.
Our largest markets are the U.S., China, Spain, Canada, Italy, France, Australia, Brazil, South Korea, and the United Kingdom.
Revenue per region 2025
In 2025, our total revenue from strategic brands was DKK 19.0 billion.
Total revenue from key products 2021-2025 (DKKm)
More from Lundbeck
Products
Our products - the proud results of years of research.
Careers
Take your next career step with Lundbeck.